JP2002526455A - 治療用たんぱく質に対する免疫応答を下方変調する方法 - Google Patents

治療用たんぱく質に対する免疫応答を下方変調する方法

Info

Publication number
JP2002526455A
JP2002526455A JP2000573762A JP2000573762A JP2002526455A JP 2002526455 A JP2002526455 A JP 2002526455A JP 2000573762 A JP2000573762 A JP 2000573762A JP 2000573762 A JP2000573762 A JP 2000573762A JP 2002526455 A JP2002526455 A JP 2002526455A
Authority
JP
Japan
Prior art keywords
agent
antibody
factor viii
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000573762A
Other languages
English (en)
Japanese (ja)
Inventor
ジアフア キアン
レオン ダブリュー． ホヤー
マリー コリンズ
ガリー エス． グレイ
Original Assignee
ジェネティックス インスティテュート インク．
アメリカン レッド クロス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネティックス インスティテュート インク．, アメリカン レッド クロス filed Critical ジェネティックス インスティテュート インク．
Publication of JP2002526455A publication Critical patent/JP2002526455A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000573762A 1998-09-21 1999-09-21 治療用たんぱく質に対する免疫応答を下方変調する方法 Withdrawn JP2002526455A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
US09/158,178 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (1)

Publication Number Publication Date
JP2002526455A true JP2002526455A (ja) 2002-08-20

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000573762A Withdrawn JP2002526455A (ja) 1998-09-21 1999-09-21 治療用たんぱく質に対する免疫応答を下方変調する方法

Country Status (21)

Country Link
EP (1) EP1115423A1 (hu)
JP (1) JP2002526455A (hu)
KR (1) KR20010085830A (hu)
CN (1) CN1331602A (hu)
AU (1) AU761206B2 (hu)
BR (1) BR9913991A (hu)
CA (1) CA2343916A1 (hu)
CZ (1) CZ20011021A3 (hu)
EA (1) EA005236B1 (hu)
HK (1) HK1039059A1 (hu)
HU (1) HUP0103960A3 (hu)
IL (1) IL142069A0 (hu)
LT (1) LT4920B (hu)
LV (1) LV12768B (hu)
MX (1) MXPA01002898A (hu)
NO (1) NO20011412L (hu)
NZ (1) NZ511034A (hu)
PL (1) PL346796A1 (hu)
SI (1) SI20626A (hu)
WO (1) WO2000016801A1 (hu)
ZA (1) ZA200103156B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180006390A (ko) * 2015-05-11 2018-01-17 해모스타틱스 리미티드 지혈 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
EP1636579A4 (en) * 2003-06-10 2011-10-05 Smiths Detection Inc SENSOR ASSEMBLY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
JPH10507758A (ja) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
TR199903141T2 (xx) * 1997-06-20 2000-09-21 Biogen, Inc. Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.
US8099877B2 (en) 2009-11-06 2012-01-24 Hexagon Metrology Ab Enhanced position detection for a CMM

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180006390A (ko) * 2015-05-11 2018-01-17 해모스타틱스 리미티드 지혈 조성물
JP2018515216A (ja) * 2015-05-11 2018-06-14 ハエモスタティクス リミテッド 止血組成物
KR102645212B1 (ko) 2015-05-11 2024-03-07 해모스타틱스 리미티드 지혈 조성물

Also Published As

Publication number Publication date
CA2343916A1 (en) 2000-03-30
AU761206B2 (en) 2003-05-29
LT4920B (lt) 2002-06-25
MXPA01002898A (es) 2002-06-04
HK1039059A1 (zh) 2002-04-12
LV12768B (lv) 2002-06-20
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (hu) 2002-02-28
BR9913991A (pt) 2001-07-03
KR20010085830A (ko) 2001-09-07
LT2001045A (en) 2002-01-25
IL142069A0 (en) 2002-03-10
WO2000016801A1 (en) 2000-03-30
PL346796A1 (en) 2002-02-25
CN1331602A (zh) 2002-01-16
HUP0103960A3 (en) 2003-09-29
SI20626A (sl) 2002-02-28
ZA200103156B (en) 2002-07-18
NO20011412D0 (no) 2001-03-20
NO20011412L (no) 2001-05-16
EA005236B1 (ru) 2004-12-30
AU6057899A (en) 2000-04-10
NZ511034A (en) 2004-03-26
WO2000016801A9 (en) 2000-10-26
CZ20011021A3 (cs) 2001-10-17
EA200100385A1 (ru) 2001-10-22
LV12768A (en) 2001-12-20

Similar Documents

Publication Publication Date Title
Qian et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
Lollar Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
JP4052524B2 (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
US20120269806A1 (en) Methods of inducing tolerance
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
IE901949L (en) Monoclonal antibodies for inducing tolerance
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
Schaub et al. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis
US20040126781A1 (en) Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
US20070092506A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
Green et al. T cell receptor stimulation, but not CD28 costimulation, is dependent on LFA‐1‐mediated events
JP2003128579A (ja) 特定種のｌｆａ−３またはｃｄ２結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法
AU761206B2 (en) Methods of downmodulating the immune response to therapeutic proteins
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
US20030161827A1 (en) Therapies that improve graft survival
Unger et al. Chronic CD40L blockade is required for long-term cardiac allograft survival with a clinically relevant CTLA4-Ig dosing regimen
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
Bril Factor VIII inhibitors in mild haemophilia A
Lobo et al. Natural IgM switches the function of LPS activated murine bone marrow dendritic cells (BMDC) to a “regulatory” DC that suppresses innate inflammation
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
MXPA99010571A (en) Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
AU4112399A (en) Ligands for induction of antigen specific apoptosis in T cells

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20061205